212 related articles for article (PubMed ID: 35552095)
1. A review of biosimilars for rheumatoid arthritis.
Conran CA; Moreland LW
Curr Opin Pharmacol; 2022 Jun; 64():102234. PubMed ID: 35552095
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E
BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Equivalence of Biosimilar and Reference Biologic Drugs in Rheumatoid Arthritis: A Systematic Review and Meta-analysis.
Ascef BO; Almeida MO; Medeiros-Ribeiro AC; Oliveira de Andrade DC; Oliveira Junior HA; de Soárez PC
JAMA Netw Open; 2023 May; 6(5):e2315872. PubMed ID: 37234004
[TBL] [Abstract][Full Text] [Related]
4. Equivalence and switching between biosimilars and reference molecules in rheumatoid arthritis: protocol for a systematic review and meta-analysis.
Ascef BO; Almeida MO; de Medeiros Ribeiro AC; Andrade DCO; de Oliveira Júnior HA; Pereira TV; de Soárez PC
Syst Rev; 2021 Jul; 10(1):205. PubMed ID: 34274019
[TBL] [Abstract][Full Text] [Related]
5. Uptake of Biosimilars and Its Economic Implication for the Treatment of Patients with Rheumatoid Arthritis in Korea.
Cho SK; Jung SY; Kim H; Song YJ; Lee K; Sung YK
J Korean Med Sci; 2021 May; 36(20):e143. PubMed ID: 34032032
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of subcutaneous infliximab versus adalimumab, etanercept and intravenous infliximab in patients with rheumatoid arthritis: a systematic literature review and meta-analysis.
Caporali R; Allanore Y; Alten R; Combe B; Durez P; Iannone F; Nurmohamed MT; Lee SJ; Kwon TS; Choi JS; Park G; Yoo DH
Expert Rev Clin Immunol; 2021 Jan; 17(1):85-99. PubMed ID: 33305638
[TBL] [Abstract][Full Text] [Related]
7. Impact of Infliximab and Etanercept Biosimilars on Biological Disease-Modifying Antirheumatic Drugs Utilisation and NHS Budget in the UK.
Aladul MI; Fitzpatrick RW; Chapman SR
BioDrugs; 2017 Dec; 31(6):533-544. PubMed ID: 29127626
[TBL] [Abstract][Full Text] [Related]
8. Biosimilars for the treatment of psoriatic arthritis.
Cantini F; Benucci M; Li Gobbi F; Franchi G; Niccoli L
Expert Rev Clin Immunol; 2019 Nov; 15(11):1195-1203. PubMed ID: 31625769
[No Abstract] [Full Text] [Related]
9. Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: a drug utilization study from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR).
Phan DB; Bewley AP; Smith CH; Mackenzie T; Griffiths CEM; Lunt M; Warren RB; Yiu ZZN
Br J Dermatol; 2023 Jul; 189(1):62-70. PubMed ID: 37016153
[TBL] [Abstract][Full Text] [Related]
10. Review of Biosimilar Trials and Data on Etanercept in Rheumatoid Arthritis.
Chadwick L; Zhao S; Mysler E; Moots RJ
Curr Rheumatol Rep; 2018 Nov; 20(12):84. PubMed ID: 30411183
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Real-World Post-approval Safety Data of Multiple Biosimilars from One Marketing-Authorization Holder After More than 18 Years Since Their First Biosimilar Launch.
Sagi S; Anjaneya P; Kalsekar S; Kottke A; Cohen HP
Drug Saf; 2023 Dec; 46(12):1391-1404. PubMed ID: 37902937
[TBL] [Abstract][Full Text] [Related]
12. CT-P13 in the treatment of rheumatoid arthritis.
Yoo DH
Expert Rev Clin Immunol; 2017 Jul; 13(7):653-666. PubMed ID: 28571501
[TBL] [Abstract][Full Text] [Related]
13. Effect of listing strategies on utilization of antitumor necrosis factor biologics infliximab and etanercept: a cross-sectional analysis from Ontario, Canada.
Fenna J; McCormack D; Kitchen S; Martins D; Gomes T; Tadrous M
J Manag Care Spec Pharm; 2021 Apr; 27(4):444-452. PubMed ID: 33769851
[No Abstract] [Full Text] [Related]
14. Adalimumab Biosimilars in Europe: An Overview of the Clinical Evidence.
Bellinvia S; Cummings JRF; Ardern-Jones MR; Edwards CJ
BioDrugs; 2019 Jun; 33(3):241-253. PubMed ID: 31111422
[TBL] [Abstract][Full Text] [Related]
15. Potential Cost Implications of Mandatory Non-Medical Switching Policies for Biologics for Rheumatic Conditions and Inflammatory Bowel Disease in Canada.
Crosby M; Tadrous M; Gomes T
Clin Pharmacol Ther; 2021 Mar; 109(3):739-745. PubMed ID: 32909249
[TBL] [Abstract][Full Text] [Related]
16. Real-world outcomes following switching from anti-TNF reference products to biosimilars for the treatment of psoriasis.
Ruda RC; Kelly KA; Feldman SR
J Dermatolog Treat; 2023 Dec; 34(1):2140569. PubMed ID: 36305624
[TBL] [Abstract][Full Text] [Related]
17. Impact of immunogenicity on efficacy and tolerability of tumour necrosis factor inhibitors: pooled analysis of biosimilar studies in rheumatoid arthritis.
Emery P; Suh CH; Weinblatt ME; Smolen JS; Keystone EC; Genovese M; Vencovsky J; Kay J; Hong E; Baek Y; Ghil J
Scand J Rheumatol; 2020 Sep; 49(5):361-370. PubMed ID: 32468892
[No Abstract] [Full Text] [Related]
18. Forty-Eight-Month Monitoring of Disease Activity in Patients with Long-Standing Rheumatoid Arthritis Treated with TNF-α Inhibitors: Time for Clinical Outcome Prediction and Biosimilar vs Biologic Originator Performance.
Colina M; Khodeir M; Rimondini R; Valentini M; Campomori F; Corvaglia S; Campana G
Clin Drug Investig; 2024 Mar; 44(3):141-148. PubMed ID: 38294672
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Adalimumab Biosimilars: Current Critical Clinical Data in Rheumatoid Arthritis.
Lu X; Hu R; Peng L; Liu M; Sun Z
Front Immunol; 2021; 12():638444. PubMed ID: 33889152
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
